Leukotriene receptor antagonist

Question 1

LTRA (montelukast)- indications in:

1. Adults
2. Children between 5-12 years old
3. Children <5 years old

Answer 1

ASTHMA

Adults
add-on therapy for asthma, where symptoms are not adequately controlled by ICS and LABA

Children (5–12 years)
alternative to LABAs as an add-on therapy where ICS are insufficient to control asthma symptoms.

Children (<5 years)
first-line preventative therapy in young children with asthma who are unable to take an ICS

Question 2

LTRA (montelukast)- common adverse effects

Answer 2

generally well tolerated

most common but mild:

• headache
• abdominal pain

increased risk of URTI

Question 3

LTRA (montelukast)- uncommon adverse effects

Answer 3

uncommon:

• hyperactivity
• reduced ability to concentrate

Question 4

LTRA (montelukast)- interactions

Answer 4

none

Question 5

LTRA (montelukast)- monitoring

Answer 5

Efficacy should be monitored by symptom diary and serial measurement of peak expiratory flow rate.